Dr. Eran Nadav​


Eran focuses on investing in the global pharmaceuticals and biotechnology sectors. Prior to joining TPG in 2007, Eran worked in the pharmaceutical industry, including positions with Eisai and J&J. Eran currently serves as Chairman of the Board of Trevi Therapeutics, and on the Boards of Collegium Pharmaceutical ShangPharma (a China-based CRO), Nutrinia and NovaSom. He was the Chairman of the

Board of Ultragenyx Pharmaceutical. Other past investments and board roles include JCR Pharmaceuticals (a Japanese biopharma company), MacroGenics, and Mayanot Eden.

Eran holds a PhD in biochemistry, MSc Magna Cum Laude, BSc Magna Cum Laude, and MBA, all from Tel Aviv University